Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	369,129	336,531	317,237	290,019	248,554	234,555
Revenue Growth	13.53%	6.08%	9.38%	16.68%	5.97%	-5.33%
Gross Profit Gross Profit Growth	218,932	196,656	182,399	160,162	132,137	130,056
Operating Income Operating Income Growth	57,236	51,514	50,414	43,915	25,119	33,064
Net Income Net Income Growth	39,902	35,048	34,859	31,730	19,275	26,482
Earnings Per Share EPS Growth	69.02	60.34	59.81	54.15	32.90	45.19
EPS Growth	17.13%	0.89%	10.44%	64.62%	-27.21%	-50.37%

Revenue by Geography

Chart

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India India Growth	33,274	36,014	34,020	27,482	26,700
USA USA Growth	143,591	144,785	139,804	112,421	105,208
Europe Europe Growth	106,882	92,361	75,633	72,430	78,813
Rest of the World Rest of the World Growth	52,784	44,078	40,562	36,222	23,835
Total Total Growth	336,531	317,237	290,019	248,554	234,555

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	99,779	105,849	82,013	63,264	62,327	45,663
Total Debt Total Debt Growth	86,298	80,728	82,629	66,476	52,862	28,513
Net Cash (Debt) Net Cash Growth	13,482	25,121	-615.9	-3,213	9,465	17,150
Net Cash Growth	22.79%	-	-	-	-44.81%	486.55%
Net Cash Per Share Net Cash Per Share Growth	23.32	43.25	-1.06	-5.48	16.15	29.27

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	59,245	55,264	39,246	24,345	23,868	50,165
Capital Expenditures CapEx Growth	-27,527	-26,858	-19,679	-27,803	-24,038	-20,529
Free Cash Flow Free Cash Flow Growth	31,717	28,406	19,568	-3,458	-170.5	29,636
Free Cash Flow Growth	-12.46%	45.17%	-	-	-	56.71%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	59.31%	58.44%	57.50%	55.23%	53.16%	55.45%
Operating Margin	15.51%	15.31%	15.89%	15.14%	10.11%	14.10%
Pretax Margin	15.80%	15.19%	15.97%	15.10%	10.51%	14.38%
Profit Margin	10.81%	10.41%	10.99%	10.94%	7.75%	11.29%
FCF Margin	8.59%	8.44%	6.17%	-1.19%	-0.07%	12.63%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov 12, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	7.000	4.000	-	4.500	3.000	9.000
Dividend Per Share Growth	0%	-	-	50.00%	-66.67%	125.00%
Dividend Yield	0.39%	0.31%	-	0.41%	0.58%	1.35%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov 12, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	26.18	21.62	19.34	20.11	15.75	14.79
Forward PE	19.77	18.02	15.91	17.77	12.19	12.83
P/FCF Ratio	32.78	26.67	34.45	-	-	13.22
PS Ratio	2.82	2.25	2.13	2.20	1.22	1.67

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error